Enhancing cancer treatment by improving immune response to tumors
Potentiating Checkpoint Blockade by Cross-Priming Tumor-Reactive T cells with In Situ Vaccination
This study is exploring a new way to boost cancer immunotherapy by helping the immune system better spot and fight tumors, using a mix of treatments like a vaccine and radiotherapy, to see if it can lead to better results for patients.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10881431 on NIH RePORTER |
What this research studies
This research investigates a novel approach to enhance the effectiveness of cancer immunotherapy by improving the immune system's ability to recognize and attack tumors. It utilizes a combination of therapies, including a vaccine that recruits immune cells, radiotherapy to prepare these cells, and specific agents to activate them. By studying this method in mouse models and analyzing samples from previous clinical trials, the research aims to understand how to better present tumor-associated antigens to the immune system, potentially leading to improved responses in patients receiving checkpoint blockade therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with specific types of cancer who have not responded adequately to existing checkpoint blockade therapies.
Not a fit: Patients with cancers that are not amenable to immune-based therapies or those who have already shown resistance to multiple treatment modalities may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that benefit a larger number of patients by enhancing their immune response to tumors.
How similar studies have performed: Previous studies have shown promising results with similar immunotherapy approaches, indicating potential for success in this novel method.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Brody, Joshua D — Icahn School of Medicine at Mount Sinai
- Study coordinator: Brody, Joshua D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.